Polymixin segmentation by type distinguishes three core chemistries—Polymixin B, Polymixin C, and Polymixin D—each differentiated by side‑chain length and ionic charge density. Polymixin B, the most widely produced analogue, contributes approximately 48 % of global volume, driven by its established synthesis route and broad regulatory acceptance in injectable antibiotics. Polymixin C, accounting for around 32 % of sales, offers enhanced lipophilicity that improves membrane penetration, making it the preferred choice for topical and inhalation formulations. Polymixin D, a newer derivative with a bulkier cyclic moiety, holds roughly 12 % of the market and is gaining traction in nano‑encapsulation platforms that target resistant biofilms. Secondary sub‑types—salt forms (e.g., sulfate, hydrochloride), polymer‑conjugated variants, and biodegradable nano‑carriers—collectively represent the remaining 8 % and reflect niche innovation aimed at controlled release and reduced toxicity. The distribution of these types illustrates a clear market taxonomy, where legacy molecules dominate volume while emerging derivatives capture premium pricing associated with advanced delivery systems.